radone
New member
- Awards
- 0
There is good scientific evidence for the use of gene therapy for follistatin and IGF-1. There is also good potential with ACTN3 (sprinter's gene) and shRNA for myostatin (myostatin inhibitor). (I am a real researcher, studying athletic performance enhancement and the treatment of muscle diseases) I am currently working on a research project related to these and some other genes. If you compare gene therapy versus injection of the gene product (peptide or protein), there are definite safety advantages to administration of the peptide. Has anyone else observed this same research? My question is related to gene therapy with IGF-1. In theory, you should be able to obtain similar results from the injection of IGF-1 peptide as you would with IGF-1 AAV gene therapy. Of course, the peptide will require frequent dosing. It has been my experience that the IGF-1 peptide does not even come close to achieving the results that gene therapy does. Any thoughts?